Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAS203 on Renal Function in Healthy Volunteers
NCT02992236Phase 1Completed
- Sponsor
- Vasopharm
- Start
- Aug 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in traumatic brain injury (TBI) comparing Placebo with VAS203 (2 arms). Primary endpoints: Renal Plasma Flow at 8 hours and Glomerular Filtration Rate at 8 hours. Started Aug 2015; status: completed.
02
Drugs
ronopterin
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT02992236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02992236.